Biondvax Pharmaceuticals (BVXV)

Kenny Green Edison Group, IR
Josh Phillipson Director of Business Development and Investor Relations
Amir Reichman Chief Executive Officer
Matthias Dobbelstein Professor at University Medical Center, Gottingen
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.
Kenny Green

Hi everyone. Good day. I would like to welcome all of you to BiondVax's Webinar. My name is Kenny Green from Edison Group and I'm part of the IR team at BiondVax. I would like to remind everyone that this conference call today is being recorded and the recording will be available later today on BiondVax's Investor Relations Web site. conference future contain performance events company. this forward-looking or of that regarding statements or note call projections will other the Please the future statements guarantee BiondVax fact These predictions will occur. they in cannot only are that and does information. that to not assume BiondVax obligation update any results events or those materially may Actual from differ projected. the risks with documents the Securities see the company's Please and identified in filed Exchange Commission. Business BiondVax. I'd over to Director of call to at Josh Relations the Development hand like Investor And now and Phillipson, please go Josh, ahead.

Josh Phillipson

like our for in would released I'm professor I Matthias business restructuring, some in-house Amir Sciences. pipeline including Thank Planck thank today everyone two Göttingen announced of event. the NanoAb Max Kenny. a XXXX you, is of provide Bank’s Reichman, at development collaboration the will European Dr. loan of this year attending to Medical Max Center Institute NanoAb and and pleased our for a including financial with for pending week. University Dobbelstein, update, were recent at our who Investment Professor our biologics results, and welcome the our progress last also and the the the recently provide Multidisciplinary manufacturing And The to he'll full the GMP UMG. the which BiondVax's fellow presenters, Amir CEO manufacturing preparations updates, Planck restructuring here Jerusalem. facility at

webinar, is open this of research, permitting pleased floor joining questions antibody will science We and results. on highlight his the Dr. of forward Dobbelstein of the we'll and end some us his the behind are very where discussion to of the at Time some we that Matthias Professor up for look answers. call the hearing nanosized

over questions on Zoom call You're at or will BiondVax's Q&A Amir? the And the time CEO box box hand Reichman. platform. with the the I to Amir any invited via that, chat submit to

Amir Reichman

nice intro for and you Josh, the you nice video. very opening and much, much for thank very and the Kenny Thank

we with for the Relations Professor as our of mention development, by Dobbelstein the together points mentioned BiondVax will give Dr. to second update Center for Göttingen recent related the the Investor one three one financial summary about include today So people. I’ll presentation that business our me, today, the Matthias pipeline Director. The third University and Medical Josh, one

happy So that with I'm we with COVID-XX to progressed the development, to with regards you pipeline the have NanoAb development. share

transfer We in are manufacturing from technology site now deep into into Jerusalem. Israel the our into Germany

manufacturing process team a the preparation prove focused therapy will inhalation process, Our fully is scale seek to then an for of NanoAb COVID-XX of inhaled concept optimization, for later the and now development be to of the of animals that up on administered COVID-XX. then as NanoAb

specifically Planck Göttingen combined Max for Omicron We that Institute December to throughout an finalized with Medical with we development it contract ensure that of NanoAb the to want that strong the research the of agreement the also XXXX, have a Center finalized as the have and the specifically exclusive for University NanoAb worldwide remind platform. in you the license we I as relates COVID-XX third variant that NanoAb, concern. us of the support and against to process was particular and treatment, the drug Omicron challenges the with efficacious collaboration have to

macular additional, will an then that BiondVax we’ll Planck platform was having and into treatment Institute nine will Now tackling psoriasis, as Max NanoAbs needs, and additional disease for such be to further exclusive the NanoAbs delivered these by be be exclusive option medical for institutes to signed the our that Medical will recent research expand collaboration with BiondVax. Göttingen, University two just worldwide And asthma, Center an the of These license psoriatic further be targets these development for further and of with NanoAbs. license arthritis known commercialization that unmet will degeneration.

As I is before the mentioned [tech] started. transfer

further our so amount and now have R&D and significant to in scale labs our acquired GMP of site quite we manufacturing. process for preparation that manufacturing equipment for the it are proof NanoAb after QC strengthened XXXX. up of And will inhalation and We can concept in after immediately that able route we of as so demonstrate animals the we human the first the the be we promised for turnaround to move to administration, in in fit

due debt For indications. to announced, The XXXX, with which BiondVax Investment lent its for 'XX of terms we built million and the €XX the Investment mostly And about in provided the as have on trust state-of-the-art a Bank. institute an BiondVax to speaks future our the in The of thorough the XX, Investment a was sales of debt December will GMP payout diligence, the complete the manufacturing conducting paid only be BiondVax in upside of and restructuring summary, in euros. agreed for millions agreed crafted to as This the And maturity European royalties. for of Bank the to in the for of we principle has just development European the has financial our of have In for net BiondVax, the runway European strategy after debt NanoAbs back time new additional due payback to paid be has further BiondVax. in the EIB the volumes allow extend the to will well XXXX. site. like €XX million, view strategy outstanding date date through EIB participation that a will bullet its be to Bank COVID-XX that and of

course, I system. our annual site the financial to to biondvax.com there review financial report, go of at XX-F Web EDGAR filed reports just that were and with also invite filed have We XXXX report, so is at the filed to everybody SEC which

round human of in studies first end -- held As COVID-XX talent the enough the $XX.X to to for top other and the of cash to of expected today, the are the now year, R&D as to to of staff we we strengthen program. been to we capabilities hiring NanoAbs to in for complete In and reported our [seat] as of million the NanoAbs. with it the regards up support cash manufacturing goes people, the we completing have as arrive our NanoAb the a have required development,

the We the our collaboration also Planck and say Max Jay be a recombinant Center protein of Vaccines, the We Green, remind Board I BiondVax will former of strengthened that CFO with XXX trial The was pre-clinical massive and that BiondVax. up Mr. the the BiondVax experience the who vast to Medical of University a recruitment drug biological with showing to with between Phase participants. want the conducted and well. has drug, that stage XX,XXX can drug, infectious from synergy clinical recombinant protein GSK the come the experience with drug bringing them Board audience Göttingen will over sites development. joined our disease III as internationally effect and had

So the is experience BiondVax. there with

was several mentioned Vaccines and an by We experience, additional as and to in years, management for standards. cash. made to my is valued having Vaccines built as have establishment with to eventually European company, roles North venture of Medicinal in $X.X and The called for manufacturing that Belgium. the Novartis billion companies. I in then company followed and can Tanabe Pharma said also, own of top our is meet global I a experience for myself, Agency of were at leadership participating Prior These was GSK in experience high working GMP in in biotech both at a testify start-up [Neuroderm] all tier transaction pharma working sold the America years level that [VAT] six Mitsubishi FDA before, the a I grade site, which big

me we COO that from the have I comes Novartis. bring and pharma entrepreneurship on team, So the with will an our also large Together experience. both with experience

both that and NanoAb Planck We UGM Planck, and therapies. XX before. Board UMG I drug quality companies the the experienced of capabilities But course, drugs development, a appreciate. of the to capabilities the on pandemic, that important many with for from their on is Planck knowledge pandemic, won leading top remind access for Max bring and I will such are have covering this Directors a world has an to tier. the knowhow. The class and side and example, might drugs explained other technologies, analysis Max and Professor and people, want Max to as science The scientists. access are of us towards that and organization equipment is and Dobbelstein just past just vastly manufacturing to aim of in by prizes risk same providing quite the they bring that for people of of not hedge for de-risk scares, their the in towards the development a by of lab the of the control and massive a Biosafety have manufacturing, based edge. physics year the R&D potent building the and days level Nobel the through platform development strategy platform specifically years each NanoAb chemistry. of BiondVax access, promising laboratory will We the over capabilities the very competitive them our is X we treat a that capability is for of of to these a run two it's having patents

hand collaborations. further over So have through NanoAb Please COVID-XX that development have COVID-XX a With license an explanation NanoAb UMG that for for and we license platform. for today for say to to Matthias I I commercialization exclusive Dobbelstein, want at will NanoAb further and that, the option of exclusive these scientific Matthias. to worldwide we additional as professor through

Matthias Dobbelstein

introduction, your a and But beyond in everybody NanoAb of nanobodies on cytokines use different of as like against to Amir Thanks remind focus for COVID-XX also talk. the that to will by diseases. this would very go And for will I are now I process we developing the much that tackle kind therapy, number of impressive therapy. exemplified

proteins cell that. virus here. on about the any what's the place by at receptor and a the of here spike first by shown right blue to without right interaction the beginning not in the infection could of interaction This cell and and this infection take SARS-CoV-X infection shown So in the is the infection virus is COVID-XX, of instrumental

the here's keeps to it it cell. comes virus, the in. in of the The So green because where virus the binds protein binding specifically shown here nanobody the neutralizes surface to spike on from that's the protein and nanobody receptor how the

it how that's works. principle the that's So

different it’s in a complicated it's to cumbersome of what nanobodies, why makes is a as different produce construct, here, you have so in chains you two heard Conventional past. may not produce. it's in composed kind, this two of and that of total. it shown look antibodies too conventional mouse the like them stable And fairly from a and antibodies can So them four change

in in various as an then an antibody it nanoantibody, is the a your to antagonist is right this small and kind a one including to bluish antibodies we will. and even we further fashion. alpacas And produce diseases. this technology but of only heavy their of you animals portion a activity serve can would fortunate still isolated So validate enough just together only you that the who And hand and in feel have that we of And chain. the side. smarter COVID-XX actually on of this improving these way. that call the antibody make with ever better against a of where to if in in this do [Dirk may Görlich] early. order this protein still the -- chain compact person come treatment NanoAb we These And you are or can pioneering target, more you in that's taking of getting such since see And by merits, nanobodies the is work composed kind actually

is larger So have advantage out of why much choice then after Well, nanobodies? one them. a a making of nanobodies library that you

talking And best from in with we're the XX a from. power If make contained up library million, binders In library a from, couple to from XXX those at NanoAb antibody XXX bacteria our and we allows so or And about clones best to as choose of target contrast, monoclonal is the we phages. you clones, to come couple X only of the a format to clones of different alpacas take to comprises strongest the chain that antibodies make of conventional single of molecules. different can many a you easily the choose there. X,XXX can mouse,

COVID-XX, against see the So is the what you and work disease, these causing sheet is next SARS-CoV-X. how on the actually virus against work nanobodies that

milliliter had infected So green you with cells tell the But picomolar infected here than keep is infecting with are exposed thoroughly that them down is concentrations, one and XX the virus actually see we the nanobodies, there that less virus with still if virus. all cells these the this dilute cell. you are nanogram that can now the from enough per the to the are these first is to we infections and virus eliminated and can

protein be of those shown receptor is So their the high surface see and extreme potency interact used that, same on the the virus and the that in explains its the here. bind purple This explained are that is is they you antiviral by binding not domain can it's receptor. to by what affinity. structure large But potency with is that nanobodies the green which the spike only in surface nanobodies, normally

why nanobodies such efficiency explains of the recently the clash So and the we nanobody the and perfect at virus of binding published receptor in the as what neutralize we have EMBO would high with that's have these Journal. frontal

more, also an model what's these animal of we one of tested in only COVID-XX. nanobodies So

is hamster, COVID-XX. the are hamsters. with they lose And -- The those So as see, gray got blue are they that the weight. They the are SARS-CoV-X. sick, box are hamsters box you it's healthy infected

that treated also protected because by the have they application healthier, by is with the different parental applications, a different these been lot hamsters these if we routes, been by especially However, from by what have been have but hamsters disease antibodies. nanobodies intranasal see

So they in actually vivo work too.

few produced from NanoAbs liter liter an exemplified supernate a yeast and NanoAbs produce it you grams locus in that's to there, you get NanoAb, find and that is goods is you of yield, it's the called easily at it's And them other can that, to of amounts, unusually make and advantage This a that see by the culture, another very you So far but calculate proteins, standard pichia the per you if this the actually high as the X,XXX you can up efficiency you NanoAbs and one pastoris. amounts in with as predominant do if here. are protein. you of There allows of see high X kilogram fermenter. and

So on heat way is you And the [IDGs]. the of production, also of can of nanobodies advantage thermostability easier as all and they are than predictor antibodies, still purification storage you some thermostability And means the an XX actually as is activity. best that a for to the boil lose features. over of wouldn't up conventional with well the all conventional production can lot NanoAbs because these these actually them top the degrees, all

hurt you remain if wouldn't temperature way, and higher a still So even reach along the would it stable. antibodies anymore

in million the Now to actually with in nanobodies large extremely you are also production affordable neutralizing Immunoglobulins opposed the these the store antibodies, a choose just can can the requirements much further They XXX They Meaning capacities. nanobodies thus to we many as can And to can meet any an them also to that adapting summarize extremely affinities engineer that conventional for needs to you advantages and of stable. library, produce those pharmacokinetics. extreme developed library, them from easily. therapy. more of and them rapidly, find and thermo nano are

So I coworkers I it experts who in leave the these that but think his I'll BiondVax are people and thank in Görlich for producing from the this who also now. work, nanobodies. with Dirk not involved are only people

I for as take and thank to move And contributions their be listening. very we you. I'll happy for people these all Thank questions thank I So you along. all your

Amir Reichman

Matthias where on remind fantastic very presentation. us this like we are interesting much very the you Thank and agenda. I'd for to

the pipeline timeline. on sciences discussing the NanoAbs will business we potential the the recent and update after now of So move reviewing and NanoAbs,

manufacturing in-house a conclude move highlights and will then conclude with will financial and we on then and our Q&A. We with

COVID-XX of NanoAb to NanoAb? COVID-XX subsiding. So seems -- you the why are why sustaining why developing COVID -- may Some wonder we today be pandemic a XX

majority be research, So of today in Fauci and indefinitely the It with we market circulate key consulting in let -- -- basically vast probably eradicated. a and by be have mentioned today that we and outbreaks will after to large believe to periodic as epidemiologists conducted experts XXXX unlikely believe be will what eliminated, the endemics. leaders and Anthony continue top opinion COVID-XX December alone

high that the shows Now in population vaccinating the we the know fight pandemic. efficacy today against

a been in take. of couple vaccines However, inoculation percentage very require the use required tough years, high demonstrated and in higher of achieving use the is introduction also population task the very of high high order It’s the protection. population, of more virus to a and infectious development is population the vaccinated and efficacy past to compliance percentages of being to and the is have the very the the that

monoclonal mouth to are adverse if Pfizer, -- milligrams ours have primary highly profile. that emergency should and expected if of think XXX disease, day-to-day Now has use to is want that time-to-time for while endemic the Matthias injection the mature that drugs the directly because to liver, market we're on low and GPs, by have to in And the adverse COVID-XX our administration as And the in to Merck brings the that bring with administered we that we drugs outpatient they have antibodies. in with, blood, that IV treatments to the will towards the will mature market and vaccines lower route amount these now the an be that beyond masks focus from highly highly the for to will of and We facility should going that to move the next be the of mostly drugs these to basically through that through to pandemic, the by versus with in more, adding we have protein believe that they're and move Görlich events also all the ones need requires sustainable other they need like and therapy be and that COVID-XX are do to from specialists. swallowed, drugs their in the one arsenal and Dobbelstein, be Professor very drugs we care is should to effects, approximately drugs these market doses authorization. and of therapeutic self the are complex of they our on working they not be remove adapted because the that competitors other administered, high believe that self-administered, just manufacturing indications also to of therapeutics directly required our current these We high approved lives, drug very current our are We dose costs, and be agent an low the targeting process Professor generating administered affected the been is in the an to of we normal efficacious also on organ, been market, need to want -- use line be much already therapeutic times drug expect of will addition to different be solutions about and very go vaccines use. all inhaled, that all go important and drug systemic thinking Matthias to to Dirk wave safer have agents. potentially very counter to What's and COVID-XX arsenal differentiated going demonstrated are directly and while nanobodies. the

many alpacas Germany treatment the to of antibodies with for the order have in antigens in already produce been required Our diseases. inoculated

these spread macular these are therapies areas available, our to believe derisking very affordable, good These can disease vastly validated, need and nice are markets for about with very strategy attention XX%, NanoAbs generate very we but there. targets particular differentiated molecular have we antibodies. because use, are the with second take easy for can to for increasing. safe these I By development of your tested never that the a it the these convenient which strategy. psoriasis, example, also X% presents we to therapeutic of psoriatic for treatment. which return nicely degeneration. asthma, investment is indications, the entity, NanoAbs have and areas that In These selecting patient agents risk drug, The that are and was and benefit of use, normally that applied. a signals done reduction CAGR of penetrate our we there before. and introduction risk, Why? on therapeutic new is of one the What's into normal For of indications and face for that of examples a already want more, are from one arthritis that a the treatment to the

yet target. a in other efficacious Many target novel, The been not is the exert order times is one the used result. to clinical

new by okay, the is the the we what indeed, partners but is in have been was there fourth here, our And concept, already platform first, NanoAbs of have one are by agent it third kind of it we commercial opportunity. animals you risk already And developed one with, therapeutic contact for the The checked are using. the and basically already that others. derisk secondly,

approved, validated. for the we molecules totally have indications So the regulators for here are been disease. different these, different, approved can can rare And but they also approve know be target

antibody already have validated of tackling been specific been result going after these work. an proven the So we for beneficial to targets the clinical patient. to exert with targets are concept the And has

the is already and billion antibody, do? majorly a analysis. edge, we NanoAb growing. antibody, what different When has been going $X.X going actually present that billion. have X introduce look months reduced. we acknowledge of at it's studies was that the the us Six it's is ago, smallest going risk we will success COVID-XX are Recent shown still We the to So research it competitive it's the which are in we to that potential estimate markets a but already characteristics with are to enable of after, that beyond need is to L.E.K. an a superior biobetter, the

these disease annual But characteristics that from generate indications introduce a than on have antibodies. that right that. for psoriasis, are monoclonal we sales estimates for sales you with is side, risk will the These that same have total superior I for monoclonal -- targets dollar market to numbers Only the are The talking better these drugs. nice the are of example, already these better are use, ability. only been higher to efficacy with and represent future, about larger update from said, that safety $XX share. and We for profile, for as much see I've be antibodies, we CAGAR recent the curb targets talking manufacture between data. once truly antibodies, with billion X% will market much validated on treating are hands looking described, economics this better convenience for we about we we or very the that will here just believe therapeutic billion we NanoAb on because XX%, our once to numbers We able

I the legal to in expect upcoming We the vivo we finalizing the we weeks. administration provided the in definitive our next The within And route of for next animals. definitive should at with be for co-inhalation will beginning. agreements, the COVID-XX proof-of-concept now at Looking documents catalysts few In as the years. announced be them, EIB. the two sign already terms explained with XXXX, agreement

a going institute. are conduct to well it renowned We in

macular directly additional clinical inhalation inhaled we the of in trials towards antibodies initiation be future I/IIa the is I NanoAbs and to first initiating proving Then publish major the that route in will NanoAb. the other in can vivo expect psoriatic development share will human also we And asthma organ. the XXXX, of be administration be COVID-XX these psoriasis, targets. thing of initiate a will the to initially But going will the the in of of explained trial, We the degeneration. to we be step news first once a and we arthritis, sign Phase affected contract. readout

for be year. Matthias with future demonstrate within we in together accomplish least able as able an believe well. And help at addition Dobbelstein that to two. we that, study In be in to already one we animals of also to the to next XXXX hopefully, some or vitro will of that expect in We that will NanoAbs, conduct

So NanoAbs on BiondVax that a generate its will competitive to where have situation several already platform. generate will hands truly

also own We the which have GMP R&D manufacturing is drug It's for and development. suited site, NanoAb facility. an a our grade well

We are at for additional recently. for in manufacturing and And the that on up equipment supplemented with process in scale process have toxicity now also we improvement, studies GMP preparation first human. fully scale and later

of are manufacturing use due more rapid much rapid quality that It's et equipment, allows is -- control much single stainless lot lower development allows rapidly much it is to risk equipment. Our more it drug site a a And a which process. delays steel when testings for -- faster required market. to cleaning, of cetera one uses

adaptable and us the timelines. of this allow it a again, process is can lot to manufacturing So allowing accelerate

well. designed FDA capacity Health, a GMP the mentioned, it's and As Israel requirements I of Ministry very meet nice and manufacturing as we of EMA, to have the and there

$XX.X million to towards first programs. our human burn $X over XXXX in trust expect in $X.X additional approximately cash for a support our helping And we for in raising their the $X As we really held financials, We December as these every to month XXXX. us December XXst. million capital We thank in quarter of million trials. million investors in have raised in

side can cap the see on the table of You company. the right

the are Encore in have the public. investor our and about shareholder, by major million float rest million, ABSs are held of approximately We and the $X.X outstanding by $XX.X

just So summarize, potential significant have you. we to for for value creation

I pipeline of NanoAb. validated with We mentioned, are the addressable as massive targeting markets,

Planck Center Institute leading have Max world two collaboration signed We institutes, in strategic University Göttingen. with lead the Medical and

going it Our treat the has we COVID-XX, to strong first a is very and competitive lead candidate edge. believe

our assumptions plan research. market validate well supported business commercial with is and to L.E.K Our a large very Consulting validated by

to We session. positioned much. thank want for in competencies. Josh you XXXX. are are to that, catalysts XXXX Q&A to back you very well several And listening. and expected with therapies unique With market have everybody that innovative the we And Kenny for Thank bring large I to and pharma then

Kenny Green

Thank Matthias. thank you, you, Amir, and

the So we'll session. for the open call now question-and-answer

can see have some So you questions. I already that some submitted of

Q&A the and will we You come do or start Q&A. the so via a chat And few can then box. to some box either via moments questions we the will for give in,

first the general? advantages question, of similar what NanoAbs in are therapies our over So

Matthias Dobbelstein


concentrations. takes stable. to and at think that point to The the the Meaning lower the potent, me side as NanoAb will we tried frequency at also can less targets doses -- That can of pace antibodies. more at neutralize be to means their if they lower developed my advantages conventional these you fact at nanobodies that I lower use have can lower I that be of any, also the these end be degraded are more than lower that applications talk. anticipate, a that time can, you mainly given same effects, make and with with

here translate those So I into clinical been directly listed that that biochemical in advantages have advantages way.

Kenny Green

Next using have, are NanoAbs? question the we what risks

Matthias Dobbelstein

that apply. as risks are for biologicals the the you So any same

still relatively molecules protein complex large compounds. to and as are compared they So molecules, small

conformation have type. that as raise consider on the case would a those of like several complex such risks Those exceptions. in they compact be try this of are well. would smaller are will NanoAb that it may, expect less that may application the you structure, facing at have have eliminate application, such risk you neutralize with I up the every to beneficial, immune eliciting be antibodies, medical is is the larger I risks if you're can that molecules and a risks. than which any as But general. what immunogenic certain of is biologicals, the target to the as always and with you of point This make tendency drug a but to that will are any a in eliminate impact and those [actually]. tight will But that usual compared here very as not impact that we and any would comes target molecule, those composed a be least of molecule same each the least general not immunological supplements at NanoAbs So more are would And be reactions. major their response is comparatively the are less conventional in what Whenever that the hope still, top and on of always

Amir Reichman

fact well answer Matthias, of the strategies -- complement the was that treatments. our with here to derisking maybe to select for the monoclonal of antibody existing like for one of targets I'd validated

we today the these validated that treatment understand for there monoclonal approved can means antibodies that of and diseases. well -- are already regulatorily were So

all, the off are these risks. more been FDA have already targeting because, the benefits to secondly, will EMA, the much the patient lower, the and of tenth will of lower that the be side monoclonal drugs the first it's molecular approved of trade and so And that. also, to side targets While either molecular the be of effects that we antibodies, anticipate or one of accurate, than between going already targeting the be NanoAbs small. about known potentially And presented size these are very specifically the these considered effects regulators,

the same So our assumption tilted small. risks targets, a think -- will is that our will benefit is is to launching that targeting be quite that while regulators we biobetter the the this risk assumption to by risk that the

it's be So going be we it's to to that approved. probably going if working, believe

Kenny Green

cost COVID What treatment the We unit estimate to therapies? COVID other have another here. relative you will do of question be retail per the

Amir Reichman

be states priced, $X,XXX $X,XXX $X,XXX But how looking for facility. outpatient approximately plus by use where it's several not and predominant at approved was look about announced time that for I retail Omicron in by is the of chair for example, cost, per the just to see at Vir/GSK, in if way, and can the the administration should FDA nevertheless -- that strain. the we So was, dose that it

at substantially We expect ours to pricing, be profitable lower price yet still competitive. and

other payer. is saving going to The we the to administered cost cetera. and to for by the that therefore ours et remind the thing everybody be designed time, reducing be is self need that Also, chair

patient. provider the and focused the the the always are We P's, payer, on three

a much in ensuring the the patient and exact it's So therefore believe to reuse the not has the more payer that better system to that most that it’s drug. the competitive affordable to and competitive and bringing of best be for only whole care the primary price We we provider. And drug safe by payer be to easier to can it it but the will able today by the we down pricing predict the and going also way. to not efficacious

manufacturing of -- be of will to can profitable reveal much we such point We us course, be and competitive more it's early we too view. for from information, but very a believe

Kenny Green

are and wait? investment which a the another backs buying we good need have, [Operator catalysts, are Instructions] is question upcoming don't we coming, what means which today So to

Amir Reichman

shown catalysts XXXX. coming a in before So we have as XXXX and list a of

for runway NanoAbs, future definitive First remove to EIB, in is five will which risk of of repayment to allow of agreement the pipeline the the continue and development development of a and debt the years, BiondVax way COVID-XX the its the next foremost NanoAbs. will that the also with

that, conducting the inhalation we be of proof-of-concept the to administration. addition In route will of

generates react. and have run then and the inhalation manufacturing the completed in the on administered But full the COVID-XX full way we formulation. then devices inhalation that that And for tier NanoAb the two humans. in be inhalation we how proof-of-concept will already top hamsters And inhale we before, a combine professor assessing us science, be have to it will our are study Dobbelstein a that suppliers treat we was treatment the nicely challenge of test of they with actually that specific show of able clinical same to infected. now order by they to show that them We It'll sick downstream, scale, in already be then shown upstream system expectations inhalation will COVID-XX. in started working that then will self and an for be react And see efficacy animals. will used for in and very will purification

already that, they development generate to to are are the already, for inoculated, receiving I alpacas, order to NanoAbs say, and that the bring the up will Planck expect let's to that that required we the several mentioned antigens boosters. in addition in and and Institute we for XXXX. then from Max Germany in the next or today In us and now injected manufacturing scale as will future indications first transferred testing, further process And Jerusalem start receive further NanoAbs months,

we And initial that work indications. NanoAbs for Jerusalem in new people future vitro them will in be, COVID and pandemic, continue going will that, and is efficacy I/IIa, of treated the that then efficacious we COVID is to NanoAb in with and to we we animals studies transferring result then means will also sick scale-up Phase in a is on they Dirk right proof-of-concept human for together in toxicity as one, will to share to mode it show to and or expect animals, now inhalation then The move to and clinical science least be then So, a trials. at the the to test it after that how of are to depends going the vitro here in It's first for similar, it generate beings, to all expect in disease vivo, to spreading. first in Matthias signs but an position the conduct the be the with COVID-XX action. the with we to

mentioned test several be are used of before, indications. indications. example degenerations may because for the that also We antibodies psoriasis, can other asthma macular arthritis I As for psoriatic indications, and these are

get in in do for we ability marketing expansion drug indications. approval, different to So -- the users each additional of indication to we time anticipate this

Kenny Green

on Just expect to do the the market? When a question first COVID-XX that. be you to follow in drug

Amir Reichman

crystal ball This is very question.

trials plan like in answering have and XXXX. were III this the -- the fact They let's approval the for efficacious already and is was they I/IIa the early year you that back of COVID, in was actually and July -- of Phase enabled already then the say of really COVID-XX finished drug if Let's by Pfizer, say last the reason infection drug no -- in December, they to then in the market. and by were they approved, now I'm filed That the to the there rate that real distribute. start and look and there by approved year Phase already they submission that we got

COVID the situation deal basically for only needs have and infection and the truly XXXX. not to and to The applied diseases the the we emphasize also this lower arsenal have and a has like humanity trials marketing case vaccine against drug. the subsides concluded market would However, expect pandemic solutions the arsenal humankind the have but amplified we And toolkit. as drug -- worst the in is clinical authorization them a where to the the mentioned, mature if for disease, options of COVID-XX of that rate, that becomes part to of with, we several I

the becomes So efficacy it XXXX to situation will quite for unfortunately, we fast. marketing worsen, case or worst filing the approval. increases our be prove bottom-line, able But to suddenly pandemic means that

much So the infection really it but shorter it rate. on depends might be

Kenny Green

there other Are question. developing Another NanoAbs, any antibodies? nano companies

Amir Reichman

a are few. There

performance the We vanguards nanobody. the to platform. this be billion. in the other XXXX at Ablynx, acquired nanobodies first their and NanoAb the last the Belgian, And be as want foremost, first blood is there, but do And NanoAbs, not nanobodies or they Sanofi $X.X one the Their was have disease. developing nanobody strongly. by very Medical to companies in nanobody. But than believe we antibody million called were different enable area. Institute several valued approved in name by represent we in they well transaction Center first superior to This in they look presented us expected introduce this were pioneers and that at was sales rare a Ablynx and looking is arsenal compete our diseases. first is a will treatment to market year, that present area So perform are University in there the team Planck of for of of and that Göttingen in of are diseases And years. grow BiondVax $XXX on are the company that There and and already trademarked capabilities that were to and million them. the will of $XXX a company, We in the as of they one at drug ours. they indeed other as capabilities Max focused are they the coming of up

we currently faster so predict than be And to others.

Matthias Dobbelstein

production to And about our targets different I than to try here. the optimized. the achieved the the production SARS-CoV-X, chain has imagine, be in mean, have entire if just way of other all I this. for is currently follow-up we result every some to, what way in from talk higher and is from we as we're not that's step Each of microorganisms. platform, and we refined been this to net And competitors But that reach down entire trying here quality folds build to affinities affinities may of the the by competitors might up -- the the The immunization thousand the case as the to well. allowed the details on of I'm that our in on you field.

Kenny Green

COVID an has other So question we by less another more rendered have than effective mutation investor. drug classes. therapies [MAB]

a So approach? is feel COVID more good that you with [pursuing] why antibodies do

Amir Reichman

One, or several a can for took that. you that, systemic like a I cannot say -- you Pfizer reasons let's with choose is suggest approach when this valid So two are that PAXLOVID, there reasons approach. for not

for have and chain process have the in you the other indications counter effects, you a up you side for However, potential drugs. the go when with potential body, the tackle biochemical you

populations, people bit situation. the for situation, populations are on risk, And that so drugs, for aim a are by the self a defeating allowed the different different many at are not the ones little that virtue specifically of our it's by indications, is at -- has by risk, regarded those protect -- not or risk counter with that that that example, to is at drug are providing

you So you are develop it. know cannot [admit] those something that really but really take

can not inhale. actually faster we with specific because efficacy, have that direct for earlier, and potentially the safer. not, eliminate specifically faster mentioned the some organs, up do target unexpected potentially higher the mess when NanoAbs affected you result with of you Matthias that directly you And by virus target. and as situation person. The thirdly the actions of we not we And it the where human generate at unfortunate don't particular do at also other result a Because or thing and beneficial you result target, body

concern are points. Yes, variants. now antibodies all including, that we of the dumped some tackle neutralize able to now develop regards One, regulators the be Omicron. monoclonal I the NanoAb by the have of because Omicron. do two see variants with we inability to to that of being Now To our to

Secondly, when we we biobetter. the market look a at are with again, at the market mature and aiming

mean that will to vaccines. mature a regulators we today scheme we So market very with the adopt that is will influenza similar believe the be one see forced the to that

to once strains, for have So people can are very you marketing you in But safety. process strain. and are And specific the your the their clinical they and most every thorough strain. just show your hand the adapt of process. the to limited small then year the to do testing you authorization, few specificities a holding every required once adjust different it's comparability manufacturers trial the very to simple And prevalent the a and very marketing of authorization vaccine distributes and influenza the vaccine, WHO year

we expect So the very that. similar business be to to

So expect the of the the once marketing to and authorization, part normal the we finish have hold we we runway changes be business.

process, a Matthias, by presented very Now as manufacturing the which adapt. NanoAbs, to is easy very simple

strain other our be expect to let's antibodies there be So nanobodies, our more much, will be than antibodies say, change will it our of speed I much if antibodies. rapid ready. and to NanoAbs, And to monoclonal monoclonal anything, a before therefore, the react ability is

Matthias Dobbelstein

may accordingly, nanobodies antibodies. to that the we more do that paper our journal, on anobodies I the just be published can at by for if quickly based process the the is looking and monoclonal compared time, the conventional known rapidly adapted in had flexible the variants all And in that and reactive NanoAbs, have this adaptable which saying and illustrate production as to the we structure at to the been by SARS-CoV-X more adapting which

that's is the out of So advantages the I exactly a can play chain where nanobodies. valid but think the for production one very questions we

Amir Reichman

because So to responders, risk may the at to the the one populations fairly they situation, a theater, et point and cetera, situation virus say, the war, in the choose target at high be drug the is of the cetera. first prescription an ambulance, COVID anticipate to they the risk if and affordable, pocket, in when going et go with expected and the to directly purse -- to NanoAbs the others ward, let's approved, their to do there have or like drug that person and inhaled also that, we out safe have

to still before clinical be take one protected day the you you hour take in several then are probably But about of go a hour others. of demonstrate to to an of on because think fairly outpatient theater. you via a But an should You inhaler, major can day the and structured just infusion an won't and the it, prophylactic should that infusion half use from that, prophylactically puffs receive differentiator if we had an trial. facility you or to the protected, of want a that's drug, you it go a

Kenny Green

We of time. to the end are almost

for time one last just have question. So we

facility over year So needs two. the there a question next the the of the is and cash including position, about value GMP assets, company's funding the or

Amir Reichman

month we capital. to million, to human. we we the all $XX.X be about here, need mentioned burn first raise going We about that money sufficient additional carry and us the I XXst think way as million December to at is this So a in to held $X

market the capital either of looking from it into deals. company, we through And funded if the raise to the can through our and game, positioning. We more bringing a situation go very we on such I it's several -- and as and are are term. find milestones. ways aiming will NASDAQ. are well with partnering, working will into options But funding, from NPV injected fully the fully raise non-dilutive short company additional opportunity, partnering, And cetera. be dilution focused capital et through competitive on portfolio value be total said, is exceeding a probably be we we diversified that now strongly so in portfolio of In where now the to the of in potential this cash are pipeline there far such other well any drugs. of the of end opportunities an and game our that other, capital a for to future will to as is will such first But open we And needed, this sublicensing a if demonstrate through sublicensing, we order strengthen

Kenny Green

Okay, could in answer questions received. questions. we we to hand at more for terms I'm questions back didn't that we directly Josh? all with still We happy Relations for contact going time be get we've would that. you BiondVax. very you have have thank And some of to your Investor That's that, if us at Josh. if to And

Josh Phillipson

on the joined who thank everyone to to like and sharing CEO for his Thank Dobbelstein results research us and today insights. his you, thank Amir Kenny. call our I particularly, and Reichman, Professor

with We together are working looking forward to you.

like -- feel words contact we As you And free anybody the before My for off? please has site. additional Amir, say available email if Investor on at IR Kenny have and you'd mentioned, sign is any Relations there to reach to out. questions. are our time, is questions information ir@biondvax.com last any do also

Amir Reichman

an presented asset to that see look to that undervalued find the want collaboration, invite two you to fundamentals, think, we for released, that into everybody it's the But assets and XX% believe the feel on like exceptional BiondVax. can site look very drug interesting truly BiondVax, to positions, we analyst are like concluded exceptional, based of around capabilities to thank team both IR I that Again, and And the with opportunity. ask realize you'd our we discount And Web for our partners I'd comparing the future cash our contact your into current we that very much talent, into be have the value capabilities. today to IP investor through BiondVax into reports to and manufacturing a to ones investment the you you to comparable participation. our we the at $XX present the of first if for or should share. in today, We And everybody year here, all, of into companies our the us. our is and time have market. independent pipeline as what were that and in truly analysis. I a per invite development in have discussions rate interest of your that their one contract thank

Josh Phillipson

Thank you.

go all may You and ahead disconnect.